Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ligelizumab dose-finding in adolescent chronic spontaneous urticaria
2017-004207-52Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing Ligelizumab dose-finding arm(s) with Placebo arm (2 arms). Primary endpoint: Primary: Change in Urticaria Activity Score (UAS7) from baseline to Week 24. Started Mar 2018; status: completed.
02
Drugs
ligelizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2017-004207-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004207-52.